Search

Rhythm Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

117.19 2.14

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

113.65

Max

116.99

Galvenie mērījumi

By Trading Economics

Ienākumi

-49M

-105M

Pārdošana

11M

71M

EPS

-0.73

Peļņas marža

-147.27

Darbinieki

414

EBITDA

5.9M

-44M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+23.41% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 3. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

901M

8B

Iepriekšējā atvēršanas cena

115.05

Iepriekšējā slēgšanas cena

117.19

Ziņu noskaņojums

By Acuity

54%

46%

273 / 340 Rangs Healthcare

Rhythm Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. aug. 19:51 UTC

Rhythm Pharmaceuticals is advancing amid broader market gains, supported by strong technology sector performance and high trading volume, despite no specific company news.

2026. g. 12. aug. 19:46 UTC

Event

Rhythm Pharmaceuticals received expanded marketing authorization for IMCIVREE in the UK. Shares are trading higher since Tuesday's close, near the upper end of their one-month range.

2026. g. 11. aug. 19:36 UTC

Social Media
News
Event

Rhythm Pharmaceuticals received expanded UK approval for IMCIVREE to treat obesity, yet shares are declining amid broader market sentiment concerns.

2026. g. 10. aug. 19:31 UTC

Rhythm Pharmaceuticals Inc shares are lower today, retracing gains after an early drop. The stock is experiencing unusually high trading volume.

2026. g. 7. aug. 20:06 UTC

News

RYTM higher after JPMorgan raised price target to $146.00.

2026. g. 6. aug. 21:05 UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, reaching a high and remaining above the 20-day moving average. No specific news was identified.

2026. g. 5. aug. 20:02 UTC

Event
News

Rhythm Pharmaceuticals shares rise as Citigroup, RBC, and Citizens raise price targets to $143, $155, and $160, respectively, reflecting growing confidence in the company.

2026. g. 4. aug. 20:13 UTC

News

Rhythm Pharmaceuticals shares are trading higher in after-market hours following CEO and CFO participation in upcoming investor conferences, enhancing visibility among stakeholders.

2026. g. 3. aug. 19:51 UTC

Rhythm Pharmaceuticals Inc shares are higher today amid unusually high trading volume, continuing the upward trend since Friday's close. No specific news was identified.

2026. g. 31. jūl. 22:56 UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, despite earlier fluctuations and no specific news identified to explain the movement.

2026. g. 30. jūl. 18:46 UTC

Rhythm Pharmaceuticals Inc shares are lower today, continuing a downward trend since Wednesday. No specific news has been identified to explain the decline.

2026. g. 29. jūl. 18:46 UTC

Rhythm Pharmaceuticals Inc shares are lower today, influenced by rising oil prices amid escalating Middle East tensions, though no specific company news was identified.

2026. g. 28. jūl. 19:11 UTC

Rhythm Pharmaceuticals Inc. shares are higher today, supported by strong trading volume and positive momentum in the biotechnology sector. No specific news was identified.

2026. g. 27. jūl. 19:33 UTC

News

RYTM trades higher after JPMorgan's Overweight rating and $145 target.

2026. g. 24. jūl. 21:01 UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, reflecting a positive shift since Friday's close despite broader market challenges.

2026. g. 21. jūl. 14:36 UTC

News

Rhythm Pharmaceuticals will report second-quarter 2026 results on August 4, contributing to higher shares amid positive market sentiment and gains in the Nasdaq 100 Index.

2026. g. 20. jūl. 20:51 UTC

Rhythm Pharmaceuticals Inc is lower in after-market trading, down significantly from Monday's close and below its 20-day moving average. No specific news was identified.

Salīdzinājums

Cenas izmaiņa

Rhythm Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

23.41% augšup

Prognoze 12 mēnešiem

Vidējais 142.47 USD  23.41%

Augstākais 160 USD

Zemākais 105 USD

Pamatojoties uz 15 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Rhythm Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

15 ratings

15

Pirkt

0

Turēt

0

Pārdot

Noskaņojums

By Acuity

273 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
help-icon Live chat